Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $146.5 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 18.97% year-over-year to $146.5 million in Q4 2025; TTM through Dec 2025 was $778.7 million, a 17.67% increase from a year earlier, with the FY2025 full-year figure at $146.5 million, down 18.97% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $146.5 million, down from $177.5 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for INBX reached as high as $307.9 million in Q4 2023 and fell as low as $146.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $218.5 million across 3 years, with a median of $217.3 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity slumped 41.29% in 2024 and declined 17.92% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $307.9 million in 2023, then tumbled by 41.29% to $180.8 million in 2024, then slipped by 18.97% to $146.5 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $146.5 million in Q4 2025, $177.5 million in Q3 2025, and $212.1 million in Q2 2025.